ERAS

Erasca is executing a high-conviction 'Blue Sky' breakout driven by a fundamental rerating of its RAS-targeting pipeline. The primary engine is the recent positive Phase 1 data for ERAS-0015 (pan-RAS molecular glue) combined with a $258M upsized financing that successfully removed dilution risk through 2028. While the broader 'Rocket Ship' basket is lagging, ERAS is decoupling as a 'Quality Speculation' play, validated by a fresh Mizuho initiation (Outperform, $16 PT) and aggressive institutional absorption of the recent offering.